Lv21
180 积分 2022-11-21 加入
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
2天前
已完结
Next-generation sequencing for PTEN testing in HR+/HER2- metastatic breast cancer
4天前
已完结
AI Should Read Mammograms Only When Confident: A Hybrid Breast Cancer Screening Reading Strategy
4天前
已完结
Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer
5天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
10天前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
22天前
已完结
Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody-drug conjugates arrived?
24天前
已完结
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
24天前
已完结
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
24天前
已完结
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
24天前
已完结
皖公网安备34019202002308
